Quoin Pharmaceuticals Reports Director/Officer Changes & Financials
Ticker: QNRX · Form: 8-K · Filed: Aug 27, 2025 · CIK: 1671502
| Field | Detail |
|---|---|
| Company | Quoin Pharmaceuticals, Ltd. (QNRX) |
| Form Type | 8-K |
| Filed Date | Aug 27, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $433,620, $108,405 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, filing, financials
Related Tickers: QNRX
TL;DR
Quoin Pharma (QNRX) filed an 8-K for director/officer changes and financials as of 8/21.
AI Summary
Quoin Pharmaceuticals, Ltd. filed an 8-K on August 27, 2025, reporting events as of August 21, 2025. The filing pertains to the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements. It also includes financial statements and exhibits.
Why It Matters
This 8-K filing indicates potential shifts in Quoin Pharmaceuticals' leadership and executive compensation, which could impact the company's strategic direction and operational stability.
Risk Assessment
Risk Level: medium — Changes in directors and officers, along with the filing of financial statements, can signal significant internal developments that may affect the company's future performance.
Key Players & Entities
- Quoin Pharmaceuticals, Ltd. (company) — Filer of the 8-K report
- August 21, 2025 (date) — Earliest event date reported
- August 27, 2025 (date) — Date of the 8-K filing
- Cellect Biotechnology Ltd. (company) — Former company name
- Cellect Biomed Ltd. (company) — Former company name
FAQ
What specific changes occurred regarding directors or officers?
The filing indicates events related to the departure of directors or certain officers, election of directors, and appointment of certain officers.
What is the effective date of the reported events?
The earliest event reported is dated August 21, 2025.
What other items are covered in this 8-K filing?
In addition to personnel changes, the filing covers compensatory arrangements of certain officers and includes financial statements and exhibits.
What was Quoin Pharmaceuticals' former name?
Quoin Pharmaceuticals, Ltd. was formerly known as Cellect Biotechnology Ltd. and Cellect Biomed Ltd.
When did the company change its name from Cellect Biomed Ltd.?
The date of the name change from Cellect Biomed Ltd. was July 21, 2016.
Filing Stats: 751 words · 3 min read · ~3 pages · Grade level 11.2 · Accepted 2025-08-27 06:06:03
Key Financial Figures
- $433,620 — at Mr. Dunn shall receive a payment of $433,620 in equal bi-weekly installments (less l
- $108,405 — the Company and Mr. Dunn, a bonus of $108,405 for the 2024 financial year (less legal
Filing Documents
- tm2524439d1_8k.htm (8-K) — 29KB
- tm2524439d1_ex10-1.htm (EX-10.1) — 151KB
- 0001104659-25-083248.txt ( ) — 360KB
- qnrx-20250821.xsd (EX-101.SCH) — 3KB
- qnrx-20250821_lab.xml (EX-101.LAB) — 33KB
- qnrx-20250821_pre.xml (EX-101.PRE) — 22KB
- tm2524439d1_8k_htm.xml (XML) — 4KB
02. Departure of Directors or Certain
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As previously reported, on July 3, 2025, Quoin Pharmaceuticals Ltd. (the "Company") and Gordon Dunn, the Company's prior Chief Financial Officer, agreed to a mutual separation. Mr. Dunn's last day as Chief Financial Officer of the Company was August 15, 2025. In connection with such separation, on August 21, 2025, the Company, through its subsidiary Quoin Pharmaceuticals, Inc., entered into a Settlement Agreement, effective as of August 15, 2025 (the "Separation Agreement"), with Mr. Dunn. Pursuant to the Separation Agreement, Mr. Dunn's employment with the Company terminated as of August 15, 2025. The Separation Agreement provides that Mr. Dunn shall receive a payment of $433,620 in equal bi-weekly installments (less legally required deductions) in lieu of his entitlement to 12 months' notice under the Service Agreement, dated as of November 1, 2021, by and between the Company and Mr. Dunn, a bonus of $108,405 for the 2024 financial year (less legally required deductions) to be paid in a lunp sum on the one year anniversary of the effective date of the Separation Agreement; and the terms of any outstanding vested but unexercised non-qualified stock options held by Mr. Dunn were amended to extend the post-termination time period in which to exercise such options from 90 days to 1 year and 9 months. The Separation Agreement also contains a release of claims provision. The foregoing description of the Separation Agreement does not purport to be complete and is subject to, and qualified in its entirety by reference to, the full text of the Separation Agreement, a copy of which is attached hereto as Exhibit 10.1 and incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.1* Settlement Agreement, effective August 15, 2025, by and between Quoin Pharmaceuticals, Inc., and Gordon Dunn 104 Cover Page Interactive Data file (embedded within the Inline XBRL document) *Exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company agrees to furnish supplementally a copy of any omitted exhibit to the SEC upon request.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. Date: August 27, 2025 QUOIN PHARMACEUTICALS LTD. By: /s/ Michael Myers Name: Dr. Michael Myers Title: Chief Executive Officer